M Haution-Bitker1, T Gilbert, A Vignoles, C Lecardonnel, S Watelet, E Blond, J Drai, M Bonnefoy. 1. Dr Marine Haution-Bitker, MD, Service de Court Séjour Gériatrique, Centre Hospitalier Lyon Sud, 165 chemin du Grand Revoyet, 69310 Pierre-Bénite, France, Tel: + 33 4 78 86 56 87, Fax: +33 4 78 86 57 27, Mail: marine.haution@chu-lyon.fr.
Abstract
OBJECTIVE: To examine the association of plasmatic and erythrocyte concentrations polyunsaturated fatty acids (PUFA) with both cognitive status and decline. DESIGN: Longitudinal observational cohort study. SETTING: Memory Clinic of Lyon Sud university hospital. PARTICIPANTS: 140 patients, aged 60 and older, were referred to the memory clinic, and successively included in the cohort, between March 2010 and February 2014. MEASUREMENTS: Concentration of ω-3 PUFA (eicosapentaenoic: EPA and docosahexaenoic: DHA) and ω-6 PUFA (arachidonic: AA), were measured at baseline in plasma and in the erythrocytes membrane. Cognitive status was assessed using the mini mental state examination (MMSE), at baseline and every six months during follow-up. The median follow-up period was of 11,5 months. RESULTS: Compared to participants with minor neurocognitive disorders (MMSE≥24), participants with major neurocognitive disorders (NCD) had lower plasmatic concentrations of EPA and DHA (p<0.05) at baseline. Erythrocyte AA and DHA concentrations were significantly lower in patients with cognitive decline (defined as a ≥2 points loss of MMSE per year), while no difference in plasmatic concentrations was observed. CONCLUSIONS: Our study suggests that ω-3 PUFA plasma concentrations (mainly EPA and DHA) could be associated with cognitive status in older people. Moreover, in this exploratory study, lower erythrocyte PUFA concentrations (AA and DHA) were associated with accelerated decline and could be proposed as a surrogate marker for prediction of cognitive decline.
OBJECTIVE: To examine the association of plasmatic and erythrocyte concentrations polyunsaturated fatty acids (PUFA) with both cognitive status and decline. DESIGN: Longitudinal observational cohort study. SETTING: Memory Clinic of Lyon Sud university hospital. PARTICIPANTS: 140 patients, aged 60 and older, were referred to the memory clinic, and successively included in the cohort, between March 2010 and February 2014. MEASUREMENTS: Concentration of ω-3 PUFA (eicosapentaenoic: EPA and docosahexaenoic: DHA) and ω-6 PUFA (arachidonic: AA), were measured at baseline in plasma and in the erythrocytes membrane. Cognitive status was assessed using the mini mental state examination (MMSE), at baseline and every six months during follow-up. The median follow-up period was of 11,5 months. RESULTS: Compared to participants with minor neurocognitive disorders (MMSE≥24), participants with major neurocognitive disorders (NCD) had lower plasmatic concentrations of EPA and DHA (p<0.05) at baseline. Erythrocyte AA and DHA concentrations were significantly lower in patients with cognitive decline (defined as a ≥2 points loss of MMSE per year), while no difference in plasmatic concentrations was observed. CONCLUSIONS: Our study suggests that ω-3 PUFA plasma concentrations (mainly EPA and DHA) could be associated with cognitive status in older people. Moreover, in this exploratory study, lower erythrocyte PUFA concentrations (AA and DHA) were associated with accelerated decline and could be proposed as a surrogate marker for prediction of cognitive decline.
Authors: Sofia Lopes da Silva; Bruno Vellas; Saskia Elemans; José Luchsinger; Patrick Kamphuis; Kristine Yaffe; John Sijben; Martine Groenendijk; Theo Stijnen Journal: Alzheimers Dement Date: 2013-10-19 Impact factor: 21.566
Authors: G Brett Moreau; Girija Ramakrishnan; Heather L Cook; Todd E Fox; Uma Nayak; Jennie Z Ma; E Ross Colgate; Beth D Kirkpatrick; Rashidul Haque; William A Petri Journal: EBioMedicine Date: 2019-05-25 Impact factor: 8.143